Trials / Completed
CompletedNCT03346837
A Study to Evaluate the Effect of 2 Drugs on the Pharmacokinetics of BMS-986205 in Healthy Subjects
A Randomized, Open-Label, Four-Cohort, Parallel Design Study to Evaluate the Effect of Itraconazole or Rifampin on the Single-Dose Pharmacokinetics of BMS-986205 in Normal Healthy Participants
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 53 (actual)
- Sponsor
- Bristol-Myers Squibb · Industry
- Sex
- All
- Age
- 18 Years – 50 Years
- Healthy volunteers
- Accepted
Summary
Assess the effects of itraconazole and rifampin on the pharmacokinetics, safety, and tolerability of BMS-986205.
Detailed description
A randomized, open-label, parallel design study in healthy participants to assess the effects of itraconazole and rifampin on the single-dose pharmacokinetics of BMS-986205. Safety and tolerability data to be collected and assessed as well.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BMS-986205 | BMS-986205 |
| DRUG | Itraconazole | Oral solution |
| DRUG | Rifampin | Tablet |
Timeline
- Start date
- 2017-11-22
- Primary completion
- 2017-12-20
- Completion
- 2017-12-20
- First posted
- 2017-11-17
- Last updated
- 2018-02-28
Locations
1 site across 1 country: United States
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT03346837. Inclusion in this directory is not an endorsement.